NAMSA has purchased Perfectus Biomed Group, a U.K.-based laboratory providing customized microbiological services. Neither company disclosed the deal’s terms. 

The acquisition of Perfectus Biomed Group increases NAMSA’s scale in the United Kingdom and globally, as it now serves clients in more than 20 locations throughout the Americas, Asia and Europe.

“NAMSA very much looks forward to expanding its European suite of laboratory services with the addition of Perfectus Biomed Group,” NAMSA CEO Dr. Christophe Berthoux said. “Perfectus brings a level of expertise and depth of knowledge in customized microbiological testing solutions. This know-how and extreme proficiency in microbiological research will help us further support clients and continue to provide solutions for medical device testing and research.” 
 
Founded in 2012, Perfectus Biomed Group delivers customized microbiological services to the medtech Industry. Perfectus, considered a leader in the United Kingdom Accreditation Body (UKAS) ISO 17025 biofilm testing industry, is focused on building strong client relationships. With unique expertise in the development and accreditation of models that represent real-world scenarios, the organization has experienced a growth trajectory over the last 10 years that includes an enhanced geographical foothold and biological solutions for novel devices.
 
“Perfectus Biomed Group is delighted to join NAMSA in its mission to deliver global medtech solutions through its people, expertise and technology. With similar values and expertise in customizing solutions for clients across the globe, we are well-aligned to achieve future success for both clients and our combined organizations,” Perfectus Biomed Group CEO Dr. Samantha Westgate said. “With the complimentary expertise and resources of NAMSA, we will serve our clients in an even greater capacity and we look forward to joining the world’s leading CRO for full continuum development services.” 
 
Helping medical device Sponsors improve healthcare since 1967, NAMSA is a medtech contract research organization (CRO) offering global end-to-end development services. Driven by its global regulatory expertise and in-depth therapeutic knowledge, NAMSA is dedicated to accelerating medical device product development, offering only the most proven solutions to move clients’ products through the development lifecycle efficiently and cost-effectively. From medical device testing; regulatory, reimbursement and quality consulting; and clinical research services, NAMSA is the industry’s partner for successful development and commercialization outcomes.
 
Perfectus Biomed Group is a CRO with laboratories in the United Kingdom and North America providing both standard and customized microbiological testing services. Perfectus has extensive experience developing “fit for purpose” experiments that mimic real-life scenarios. Clients are supported throughout product development, and the Perfectus team specializes in method adaptation and customization, supporting the development and regulatory approval of typical and atypical medical devices. The U.K. facility is GLP-compliant and offers UKAS accredited contract testing.